Use case · Launch
Get covered faster, on evidence from real patients.
Payers are deciding right now. Show them effectiveness and tolerability in the people actually taking it, from records that already exist.
See what’s in the data →Why it matters now
Payers ask about the patients you are treating now.
They want to see it working in people with three comorbidities and a prior line of therapy. That population is in here, with the history behind them, and a coverage decision is live this quarter.
What you get
Four things you can do in the first year.
Generate post-approval evidence fast
Effectiveness and tolerability in the population that’s actually taking it, from records that already exist.
Answer a payer inside a week
Rapid-turn cohorts when a formulary committee asks a question you didn’t plan for. Days, while the question is still live.
See how it’s prescribed against the label
Where practice has drifted from the label, and whether outcomes follow. That’s the evidence behind both your medical education and your risk picture.
Give your field teams something local
Site and region-level insight your MSLs and access teams can take into a conversation, with the local detail their conversation turns on.
Where teams use it
Seven jobs this does in year one.
Formulary dossier evidence
Market Access · HEORReal-world effectiveness by subgroup
Field medicalTolerability and discontinuation evidence
Medical AffairsPrior authorisation objection handling
Medical AffairsMSL territory insight
HEORLabel-concordant versus real practice
Market AccessPublication-grade real-world cohorts
RWE
Payer asked you something new? Send us the question. We’ll show you what the data covers before you spend anything.
Tell us which payer is next.
We’ll show you what we can put in front of them, and how quickly.